1h Free Analyst Time
The oligonucleotide synthesis market is forecasted to grow by USD 3374.04 million during 2023-2028, accelerating at a CAGR of 13.54% during the forecast period. The report on the oligonucleotide synthesis market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing shift toward RNA-based therapeutics, increasing use of oligonucleotides as therapeutic and diagnostic tools, and technological innovations in oligonucleotide synthesis.
The oligonucleotide synthesis market is segmented as below:
By Application
- PCR primers
- PCR assays and panels
- DNA microarrays
- Fluorescence in situ hybridization
- Sequencing and others
By End-user
- Pharmaceutical and biotechnology companies
- Research and academic institutes
- Diagnostic laboratories
- Hospitals
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the oligonucleotide synthesis market covers the following areas:
- Oligonucleotide synthesis market sizing
- Oligonucleotide synthesis market forecast
- Oligonucleotide synthesis market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global oligonucleotide synthesis market: Agilent Technologies Inc., Ajinomoto Bio Pharma. , Alnylam Pharmaceuticals Inc., Amgen Inc., Ansa Biotechnologies, Bio Synthesis Inc, Biogen Inc., Biotage AB, Danaher Corp., Eurofins Scientific SE, General Electric Co., Ionis Pharmaceuticals Inc., Kaneka Corp., LGC Science Group Holdings Ltd., Merck KGaA, Mettler Toledo International Inc., QIAGEN NV, Sarepta Therapeutics Inc., Synbio Technologies, Syngene International Ltd., and Thermo Fisher Scientific Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is integration of AI and automation in oligonucleotide synthesis."
According to the report, one of the major drivers for this market is the growing shift toward RNA-based therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies Inc.
- Ajinomoto Bio Pharma.
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- Ansa Biotechnologies
- Bio Synthesis Inc
- Biogen Inc.
- Biotage AB
- Danaher Corp.
- Eurofins Scientific SE
- General Electric Co.
- Ionis Pharmaceuticals Inc.
- Kaneka Corp.
- LGC Science Group Holdings Ltd.
- Merck KGaA
- Mettler Toledo International Inc.
- QIAGEN NV
- Sarepta Therapeutics Inc.
- Synbio Technologies
- Syngene International Ltd.
- Thermo Fisher Scientific Inc.